Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-07-08
2008-07-08
Stockton, Laura L. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S409000, C514S424000, C548S214000, C548S408000, C548S550000
Reexamination Certificate
active
07396846
ABSTRACT:
This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.
REFERENCES:
patent: 3711495 (1973-01-01), Kulsa et al.
patent: 3984426 (1976-10-01), Winkelmann et al.
patent: 5206235 (1993-04-01), Fisher et al.
patent: 5242903 (1993-09-01), Bender et al.
patent: 5380866 (1995-01-01), Barnett et al.
patent: 5401851 (1995-03-01), Boyd et al.
patent: 5459156 (1995-10-01), Muller-Gliemann et al.
patent: 5492916 (1996-02-01), Marriello et al.
patent: 5492920 (1996-02-01), Chen et al.
patent: 5494919 (1996-02-01), Marriello et al.
patent: 5559128 (1996-09-01), Chakravarty et al.
patent: 5574167 (1996-11-01), Jaber
patent: 5578593 (1996-11-01), Chen et al.
patent: 5583130 (1996-12-01), Bochis et al.
patent: 5652235 (1997-07-01), Chen et al.
patent: 5661161 (1997-08-01), Anthony et al.
patent: 5663146 (1997-09-01), Bowers et al.
patent: 5663171 (1997-09-01), Chen et al.
patent: 5700827 (1997-12-01), Schnorrenberg et al.
patent: 5721250 (1998-02-01), Morriello et al.
patent: 5756528 (1998-05-01), Anthony et al.
patent: 5773441 (1998-06-01), Hipskind et al.
patent: 5798337 (1998-08-01), Somers et al.
patent: 5830855 (1998-11-01), Takemoto
patent: 6046333 (2000-04-01), Dorziotis et al.
patent: 6329342 (2001-12-01), Kauffman et al.
patent: 6639076 (2003-10-01), Hauser et al.
patent: 0 662 481 (1993-08-01), None
patent: 0 615977 (1994-09-01), None
patent: 0 761219 (1996-08-01), None
patent: 0 761 220 (1997-12-01), None
patent: WO 94/13696 (1994-06-01), None
patent: WO 94/13696 (1994-06-01), None
patent: WO 95/11029 (1995-04-01), None
patent: WO 96/15148 (1996-05-01), None
patent: WO 96/35713 (1996-11-01), None
patent: WO 96/38471 (1996-12-01), None
patent: WO 97/15573 (1997-05-01), None
patent: WO 97/24369 (1997-07-01), None
patent: WO 97/24369 (1997-07-01), None
patent: WO 97/34604 (1997-09-01), None
patent: WO 97/41878 (1997-11-01), None
patent: WO 98/16527 (1998-04-01), None
patent: WO 98/18815 (1998-05-01), None
patent: 0 761 219 (1998-12-01), None
patent: WO 98/58948 (1998-12-01), None
patent: WO 99 08697 (1999-02-01), None
patent: WO 99/08699 (1999-02-01), None
patent: WO 00/12047 (2000-03-01), None
patent: WO 00/49037 (2000-08-01), None
patent: WO 00/49037 (2000-08-01), None
patent: WO-02/32888 (2002-04-01), None
Paterson et al., Arch Dis Child, Apr. 2003, 88(4), pp. 283-285.
Burman et al. (Endocrine Reviews, 2001, 22(6), pp. 787-799.
Synthesis of 4-Nitroimidazoles with 1-Substituents Containing Acid, Ester or Phenol Functions, and Radiosensitizing Efficiency of Some of These Compounds, Suwinski, et al., Arch. Pharm., vol. 325, pp. 317-324 (1992).
Synthetic Approaches to the ‘Azole’ Peptide Mimetics, Gordon, et al., Tetrahedron Letters, vol. 34, No. 12, pp. 1901-1904 (1993).
Chem. Abst. No. 130:209977, Kaufffman, et al.,Treatment of Congestive Heart Failure with Growth Hormone Secretagogues, Kauffman, et al. application of WO 99/08697, Aug. 19, 1998.
Chem. Abst. No. 130:182769, Dodge, et al.,Preparation of Heterocyclic Peptide Derivatives as Growth Hormone Secretagogues, application of WO 9908699, |Aug. 19, 1998.
New Highly Potent Dipeptide Growth Hormone Secretagogues with Low Molecular Weight: Eur. J. Med. Chem. 35, pp. 599-618 (2000).
Growth Hormone Secretagogues Derived from NN703 with Hydrazides as C-terminal: Eur. J. Med. Chem. 35, pp. 487-497 (2000).
Chem. Abst. No. 119:261758, Uzunov, et al.,Some Aspects of the Enantiorecognition of Derivatized Primary Amines on a Pirkle-Type Chiral Stationary Phase Utilizing Tocainide and Mexiletine as Model Compounds, (1993).
Chem. Abst. No. 138:221510, Kim et al.,Synthesis and Antiinflammatory-Analgesic Activity of Monovalent and Bivalent Aminoantipyrines(2002).
Evers Britta
Gerd Ruehter
Martin De La Nava Eva Maria
Tebbe Mark Joseph
Eli Lilly and Company
Myers James B.
Stockton Laura L.
LandOfFree
Growth hormone secretagogues does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Growth hormone secretagogues, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Growth hormone secretagogues will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2799692